From: Subject: Best Dx/Best Rx: Bipolar Disorder and Depression Date: Wed, 3 Jun 2009 23:03:25 -0700 MIME-Version: 1.0 Content-Type: multipart/related; type="text/html"; boundary="----=_NextPart_000_0092_01C9E49F.7FE2E900" X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.5579 This is a multi-part message in MIME format. ------=_NextPart_000_0092_01C9E49F.7FE2E900 Content-Type: text/html; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: mhtml:file://C:\pocketnotes\bipolar2004.mht Best Dx/Best Rx: Bipolar Disorder and = Depression




Bipol= ar=20 Disorder

Depre= ssion=20


Bipolar=20 Disorder

Michael T. Compton, M.D., M.P.H.

Charles B. Nemeroff, M.D., Ph.D.
Emory = University=20 School of Medicine

Defin= ition/Key=20 Clinical Features
Diffe= rential=20 Diagnosis
Best = Tests
Best = Therapy
Best = References


Definition/Key Clinical=20 Features

  • Onset usually in late adolescence or early=20 adulthood=20
  • Not caused by a substance or a general medical = condition=20
  • Bipolar I disorder: one or more manic or mixed = episodes,=20 often alternating with major depressive episodes=20
  • Bipolar II disorder: recurrent major = depressive episodes=20 with hypomanic episodes=20
  • Cyclothymic disorder: at least 2 yr of = fluctuating mood=20 disturbance involving numerous periods of hypomanic symptoms and = numerous=20 periods of depressive symptoms=20
  • Rapid cycling bipolar disorder:≥ 4 = episodes within 1=20 yr=20
    • Typically develops late in the course of=20 illness=20
    • More common in women
  • Manic episode=20
    • Distinct period of abnormally elevated, = expansive, or=20 irritable mood lasting at least 1 wk=20
    • Includes≥ 3 of these symptoms (4 if = mood is only=20 irritable):=20
      • Inflated self-esteem or grandiosity =
      • Decreased need for sleep=20
      • Being more talkative than usual or feeling = need to=20 keep talking=20
      • Flight of ideas or sense that thoughts are = racing=20
      • Distractibility=20
      • Increased goal-directed activity or = psychomotor=20 agitation=20
      • Excessive involvement in pleasurable = activities that=20 have a high potential for painful consequences
    • About half of manic episodes include = psychotic=20 features (e.g., grandiose delusions or auditory = hallucinations)=20
    • About a quarter of manic patients have=20 hallucinations
  • Hypomanic episode=20
    • Distinct period of elevated, expansive, or = irritable=20 mood lasting at least 4 days=20
    • Includes≥ 3 symptoms of a manic = episode (4 if the mood=20 is only irritable)=20
    • No psychotic features are present =
  • Mixed episode=20
    • Major depressive episode and manic episode=20 simultaneously within 1 wk
    • Patients are dysphoric but hyperactive, = agitated, and=20 unable to sleep

3D""=20 bac= k to=20 top

Differential = Diagnosis

  • Other psychiatric conditions=20
    • Schizophrenia
    • Schizoaffective disorder=20
      • A primary psychotic disorder in which a = major=20 depressive episode, a manic episode, or a mixed episode occurs and = psychotic symptoms are present for at least 2 wk in the absence of = prominent mood symptoms
    • Personality disorders=20
      • Certain personality disorders are = characterized by=20 chronic and pervasive rapidly fluctuating affective = lability=20
      • Many patients with cluster B personality = disorders=20 (e.g., borderline personality disorder) may also meet DSM-IV = criteria for=20 dysthymic disorder, bipolar II disorder, or cyclothymic = disorder=20
    • Drug abuse=20
      • Alcohol=20
      • Amphetamines=20
      • Hallucinogens=20
      • Cocaine=20
      • Urine or blood toxicologic screens = necessary to=20 differentiate primary mania from a substance-induced mood disorder = with=20 manic features=20
        • Because comorbidity is common, a = positive urine=20 drug screen does not exclude a primary bipolar disorder=20
    • Delirium, dementia, and medical illnesses, = especially=20 in elderly patients

3D""=20 bac= k to=20 top

 

Best=20 Tests

Thorough Medical and = Psychiatric=20 Evaluation=20
  • Medical history and physical = examination=20
  • Detailed substance-use history
  • Thorough mental status examination findings = may include=20 the following:=20
    • Eccentric dress, brightly colored clothing, = excessive=20 make-up, or multiple pieces of jewelry=20
    • Euphoria, excitement, intrusiveness, or=20 irritability=20
    • Psychomotor agitation and an increase in = goal-directed=20 activity=20
    • Increased rate and rhythm of speech=20
    • Flight of ideas/racing thoughts=20
    • Elevated self-worth, grandiosity, = mood-congruent=20 psychotic features
  • Cognitive assessment may show the = following:=20
    • Memory impairment=20
    • Difficulties with attention and = concentration=20
  • Risk assessment for self-care and = suicidality=20
Laboratory Tests=20

  • Urine drug screen=20
  • Blood chemistries=20
  • Thyroid function studies=20
  • Syphilis serology

    3D""=20 bac= k to=20 top

    Best=20 Therapy

    • Hospitalization for acute mania=20
    • Drug treatment for bipolar disorder=20
      • Combination therapy often necessary=20
      • Lithium: gold standard=20
        • Assess renal and thyroid function before=20 initiating=20
        • ECG before initiating=20
        • Avoid NSAIDs and diuretics=20
        • Maintain uniform salt intake=20
        • Monitor serum levels periodically=20
          • Measure 10=9612 hr after last = dose=20
          • Measure 4=965 days after last dosage = change=20
        • Monitor BUN, serum creatinine, TSH every 6 = mo=20
        • Side effects: cognitive slowing, nausea, = diarrhea,=20 polyuria, polydipsia, weight gain, tremor, metallic taste in the=20 mouth=20
        • Dose: lithium carbonate=20
          • Initial: 300 mg t.i.d. or 450 mg = b.i.d.=20
          • Maintenance: 900=961,800 mg/day=20
          • Therapeutic blood level: 0.8=961.2 = mEq/L=20
        • Cost/mo: $38
      • Anticonvulsants=20
        • Valproic acid or divalproex sodium: more = effective=20 for manias that are dysphoric or mixed and for rapid = cycling=20
          • Assess CBC and liver function before=20 starting=20
          • Take with food=20
          • Dose: initial, 250 mg b.i.d.; = maintenance,=20 750=962,000 mg/day=20
          • Therapeutic blood level: 100=96125 = mg/L=20
          • Cost/mo: $72
        • Carbamazepine: not approved for = mania=20
          • Assess CBC and liver function before=20 starting=20
          • Monitor for drug-drug interactions and=20 autoinduction=20
          • Dose: initial, 100=96200 mg b.i.d.; = maintenance,=20 400=96600 mg/day=20
          • Therapeutic blood level: 6=9610 = =B5g/ml=20
          • Cost/mo: $17
        • Lamotrigine: for the maintenance treatment = of adults=20 with bipolar I disorder to delay the time to occurrence of mood = episodes=20 (depression, mania, hypomania, mixed episodes) in patients treated = for=20 acute mood episodes with standard therapy (more robust in bipolar=20 depression than mania)=20
          • Dose: 25 mg/day for 2 weeks; 50 mg/day = for 2=20 weeks; 100 mg/day for week 5; 200 mg/day for week 6=20
          • Slower titrations are required for = patients taking=20 carbamazepine, phenytoin, phenobarbital, primidone, rifampin, or = valproate because of risk of severe rash=20
          • Cost/mo: $720
        • Atypical antipsychotics=20
          • Risperidone=20
            • Dose: initial, 1=962 mg/day; = maintenance, 2=966=20 mg/day=20
            • Cost/mo: $394
          • Olanzapine=20
            • Dose: initial, 5=9610 mg/day; = maintenance, 10=9620=20 mg/day=20
            • Cost/mo: $640
          • Quetiapine=20
            • Dose: initial, 100=96200 mg/day; = maintenance,=20 400=96800 mg/day=20
            • Cost/mo: $668
          • Ziprasidone=20
            • Dose: initial, 20 mg b.i.d.; = maintenance, 40=9680=20 mg b.i.d.=20
            • Cost/mo: $162
          • Aripiprazole=20
            • Dose: initial, 5=9615 mg/day; = maintenance, 15=9630=20 mg/day=20
            • Cost/mo: $445=20
    • Drug treatment for depression associated with = bipolar=20 disorder=20
          • Lithium for mild depression=20
          • Antidepressant after mood = stabilization=20
          • Lamotrigine=20
            • Dose: 25 mg/day for 2 weeks; 50 mg/day = for 2=20 weeks; 100 mg/day for week 5; 200 mg/day for week 6=20
            • Slower titrations are required for = patients=20 taking carbamazepine, phenytoin, phenobarbital, primidone, = rifampin,=20 or valproate because of risk of severe rash=20
            • Cost/mo: $720 =
    • Drug treatment for psychotic symptoms = associated with a=20 manic episode=20
          • Atypical antipsychotic agents=20
    • Psychotherapy: useful as adjunctive = treatment=20

            3D""=20 bac= k to=20 top


            Best References

            American Psychiatric Association: Am J Psychiatry = 159(suppl):1, 2002 [PMID 11958165]

            Bearden CE, et al: Bipolar Disorders 3:106, 2001 = [PMID=20 11465675]

            Bowden CL: J Clin Psychiatry 66(suppl 1):3, 2005 = [PMID=20 15693745]

            De Leon OA: Harv Rev Psychiatry 9:209, 2001 [PMID = 11553525]


            January=20 2007


            3D""=20 bac= k to=20 top

            Depression

            Michael T. Compton, M.D., M.P.H.
            Emory University School of Medicine

            Charles B. Nemeroff, M.D., Ph.D.
            Emory = University=20 School of Medicine

            Defin= ition/Key=20 Clinical Features
            Diffe= rential=20 Diagnosis
            Best = Tests
            Best = Therapy
            Best= =20 References


            Definition/Key Clinical=20 Features

            • Distinguished from normal sadness and grief by = severity,=20 pervasiveness, and duration of mood disturbance and by presence of=20 neurovegetative abnormalities and other symptoms=20
            • Neurovegetative abnormalities=20
              • Sleep disturbance (most often insomnia with=20 early-morning awakening)=20
              • Change in appetite (usually anorexia) =
              • Decreased energy=20
              • Psychomotor abnormalities (slowed = thinking/movement=20 and speech or agitation)=20
              • Diurnal variation in mood (typically worse = in=20 morning)
            • Other symptoms=20
              • Depressed mood (may be irritability or loss = of=20 interest)=20
              • Loss of enjoyment of usual activities (e.g., = eating,=20 work, sex, hobbies, time with family and friends)=20
              • Loss of hope=20
              • Diminished self-esteem=20
              • Difficulty concentrating=20
              • Poor memory=20
              • Ruminations and excessive or inappropriate=20 guilt=20
              • Suicidal thoughts or recurrent thoughts of=20 death


            3D""=20 bac= k to=20 top

            Differential = Diagnosis

            • Most common causes of secondary = depression:=20
              • Alcohol abuse or dependence=20
              • Alzheimer=92s disease=20
              • Substance abuse or dependence=20
              • Parkinson=92s disease=20
              • Serious medical illness=20
              • Stroke

            Red Flags

            • Post-MI patients: 1-yr mortality higher with=20 depression=20
            • Women > 67 yr: overall mortality higher = with more=20 depressive symptoms; risk of falls and fractures greater with=20 depression=20
            • Elderly patients: suicide is major risk in the = depressed=20
            • Adolescents and young adults 15=9624 yr old: = suicide is=20 third leading cause of death

             


            3D""=20 bac= k to=20 top

            Best=20 Tests

            • No definitive biologic marker=20
            • Clinical observation (DSM-IV)=20
            • Brief questionnaires=20
              • Two-question test=20
              • Center for Epidemiologic Studies Depression=20 Questionnaire (CES-D) (10-item self-assessment)=20
              • Geriatric Depression Scale (GDS) (15-item=20 self-assessment) (for patients > 60 yr)
              • Primary Care Evaluation of Mental Disorders = Patient=20 Health Questionnaire (PRIME-MD PHQ) (nine-item = self-assessment)=20

            3D""=20 bac= k to=20 top

            Best=20 Therapy

            Psychotherapy

            • Cognitive-behavioral therapy effective in = acute=20 treatment of major depression and dysthymic disorder of mild to = moderate=20 severity=20
            • Combination of psychotherapy and medication = may be more=20 effective than either alone


            Electroconvulsive Therapy

            • Single most effective therapy for acute = treatment of=20 serious major depression=20
            • Often indicated for treatment of depression = associated=20 with the following=20
              • Medication resistance or intolerance=20
              • Psychotic symptoms=20
              • Catatonia=20
              • Medical illness that contraindicates drug=20 treatment=20
              • Acute mania=20
              • Active suicidal ideation (short-term = protective=20 effect)
            • Contraindicated in presence of increased = cranial=20 pressure

            Antidepressants

            • Selective serotonin reuptake inhibitors =
              • Citalopram: 20 mg/day initially, then = typically=20 doubled in 1 wk in cases of severe or recurrent depression; = up to 60 mg/day in event of nonresponse=20
                • Dose: 40 mg/day (20=9660 mg/day)=20
                • Cost/mo: $195
              • Escitalopram: 10 mg/day initially=20
                • Dose: 10 mg/day (10=9630 mg/day)=20
                • Cost/mo: $176
              • Fluoxetine: 20 mg/day q.a.m. initially; = reduce to 10=20 mg/day for patients with side effects=20
                • Dose: 20 mg/day (10=9680 mg/day)=20
                • Cost/mo: $92
              • Fluvoxamine: 50 mg/day initially, with = target dosage=20 of 150=96250 mg/day=20
                • Dose: 200 mg/day (50-300 mg/day)=20
                • Cost/mo: $176
              • Paroxetine: 20 mg initially in morning or = evening; 10=20 mg/day in elderly or patients with hepatic or renal dysfunction or = in=20 patients who do not tolerate 20 mg/day dosage; increase in 10 mg = increments=20 up to 50 mg/day in healthy adults (40 mg/day in the elderly) who do = not=20 respond after 4 wk=20
                • Dose: 20 mg/day (10-50 mg/day)=20
                • Cost/mo: $143
              • Sertraline: 50 mg/day initially, with target = dosage of=20 100=96150 mg/day in healthy adults=20
                • Dose: 100-150 mg/day (50-200 = mg/day)=20
                • Cost/mo: $148
            • Other New Antidepressants
              • Mirtazapine (α2 blocker, = 5-HT2=20 blocker, 5-HT3 blocker)=20
                • Dose: 30 mg/day=20
                • Cost/mo: $43
              • Bupropion SR: start treatment at 100 mg = b.i.d. and=20 increase to 100 mg t.i.d. on fourth day of treatment; may increase = to=20 maximum of 450 mg/day=20
                • Dose: 300-400 mg/day=20
                • Cost/mo: $214
              • Reboxetine: not available in U.S.=20
                • Dose: 8-10 mg/day
              • Nefazodone=20
                • Dose: 150-400 mg/day=20
                • Cost/mo: $46
              • Trazodone=20
                • Dose: 150-400 mg/day=20
                • Cost/mo: $19
              • Venlafaxine XR=20
                • Dose: 75-225 mg/day=20
                • Cost/mo: $185
            • Tricyclic antidepressants and related agents: = Use as=20 second- or third-line pharmacotherapy when insufficient response to = SSRI or=20 other antidepressant; increase dosage gradually (e.g., by 25=9650 = mg/wk) until=20 achieving therapeutic dose=20
              • Amitriptyline=20
                • Dose (range): 150-200 mg/day (75-300 = mg/day)=20
                • Cost/mo: $7
              • Amoxapine=20
                • Dose (range): 150-200 mg/day (75-300 = mg/day)=20
                • Cost/mo: $91
              • Clomipramine=20
                • Dose (range): 150-200 mg/day (75-250 = mg/day)=20
                • Cost/mo: $81
              • Desipramine=20
                • Dose (range): 150-200 mg/day (75-300 = mg/day)=20
                • Cost/mo: $44
              • Doxepine=20
                • Dose (range): 150-200 mg/day (75-300 = mg/day)=20
                • Cost/mo: $20
              • Imipramine=20
                • Dose (range): 150-200 mg/day (75-300 = mg/day)=20
                • Cost/mo: $40
              • Maprotiline=20
                • Dose (range): 150-200 mg/day (75-225 = mg/day)=20
                • Cost/mo: $50
              • Nortriptyline: more potent than other TCAs; = begin at=20 10-25 mg/day=20
                • Dose (range): 75-100 mg/day (40-150 = mg/day)=20
                • Cost/mo: $26
              • Protriptyline: more potent than other TCAs; = begin at=20 10-25 mg/day=20
                • Dose (range): 30 mg/day (15-60 = mg/day)=20
                • Cost/mo: $235
              • Trimipramine: more potent than other TCAs; = begin at=20 10-25 mg/day=20
                • Dose (range): 150-200 mg/day (75-300 = mg/day)=20
                • Cost/mo: $171
            • Monoamine oxidase inhibitors: Patients taking=20 nonselective MAOIs must avoid foods or meds that contain tyramine or = other=20 pressor amines; interactions with SSRIs may also occur=20
              • Isocarboxazid=20
                • Dose: 30 mg/day; range, 20-60 = mg/day=20
                • Cost/mo: $128
              • Phenelzine: If no improvement in 3-4 wk, = dosage may=20 increase to as high as 90 mg/day.=20
                • Dose: 60-75 mg/day; range, 60-90 = mg/day=20
              • Tranylcypromine=20
                • Dose: 30 mg/day; range, 20-90 = mg/day=20
                • Cost/mo: $210 =

            Treatment-Resistant Depression

            • Experienced by up to 30% of patients=20
            • If initial antidepressant drug has been given = at full=20 therapeutic dose with no improvement after 4-6 wk, change drug=20
            • If initial antidepressant drug has caused = partial=20 response, augment with lithium, 300 mg t.i.d.=20
            • If SSRIs are ineffective, alternative is to = add=20 bupropion, 150-300 mg/day, or another newer agent, or TCA=20
            • Consider electroconvulsive therapy early in = course of=20 treatment

            Pregnancy and Postpartum = Depression

            • Many antidepressant drugs are relatively safe = for=20 pregnant woman and fetus=20
            • Limited courses of fluoxetine or = cognitive-behavioral=20 therapy are effective in treating postpartum depression =



            3D""=20 bac= k to=20 top

            Best = References

            Davis: Essent Psychopharmacol 2:309, = 1998

            Keller, et al: JAMA 280:1665, 1998

            Silverstone, et al: J Clin Psychiatry 60:22,=20 1999

            October=20 2004


            Michael T. Compton, M.D., M.P.H, has = received=20 research grants from the Emory Medical Care Foundation and has been a = consultant=20 for AstraZeneca and Medscape. Charles B. Nemeroff, M.D., Ph.D., holds = stock in=20 Corcept Therapeutics, Inc. and Neurocrine Biosciences, Inc., and has = received=20 grants for clinical research from, served as consultant for, or been a = member of=20 the speakers=92 bureaus of the following companies and organizations: = Abbott=20 Laboratories; Acadia Pharmaceuticals, Inc.; the American Foundation for = Suicide=20 Prevention; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Co.; = Corcept=20 Therapeutics, Inc.; Cypress Bioscience, Inc.; Cyberonics, Inc.; Eli = Lilly and=20 Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Janssen = Pharmaceutica=20 Products, LP; Merck & Co., Inc.; the National Alliance for Research = on=20 Schizophrenia and Depression; the National Institute of Mental Health;=20 Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corp.; Organon=20 International, Inc.; Otsuka America, Ltd.; Pfizer, Inc.; Sanofi-Aventis; = SCIREX;=20 Somerset Pharmaceuticals, Inc.; Stanley Foundation/NAMI Research = Institute; and=20 Wyeth.

            3D""=20 bac= k to=20 top
            =A9 2008 BC Decker Inc. All rights = reserved.